Update on the treatment of recurrent ovarian cancer

Women's Health

Volumn 2, Issue 1, 2006, Pages 127-139

  Eltabbakh, Gamal H ^a   Goodrich, Scott ^b  

^a Lake Champlain Gynecologic Oncology   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Chemotherapy; Cytoreductive surgery; Ovarian cancer; Recurrent ovarian cancer; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL; PLATINUM DERIVATIVE; PRODRUG; TAXANE DERIVATIVE; TOPOTECAN;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC TEST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER TOXICITY; MAINTENANCE THERAPY; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RECURRENT CANCER; REVIEW; STOMATITIS; THROMBOCYTOPENIA; VIRAL GENE THERAPY;

EID: 33646805789     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.2.1.127     Document Type: Review

References (70)

1. Parkin DM, Pisani P. Ferlay J: Global cancer statistics. CA Cancer J. Clin. 49, 33-64 (1999).
2. Menon U, Jacobs IJ: Tumor markers. In: Principles and Practice of Gynecologic Oncology (3rd Edition). Hoskins WJ, Perez CA, Young RC (Eds). Lipincott Williams & Wilkins, PA, USA 164-168 (2000).
3. Markman M, Bookman MA: Second-line treatment of ovarian cancer. Oncologist 5, 26-35 (2003).
4. Tay EH, Grant PT, Gebski V, Hacker NF: Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet. Gynecol. 99, 1008-1013 (2002).
5. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE: Defining progression of ovarian carcinoma during follow-up according to CA125: a North Thames Ovary Group Study. Ann. Oncol. 7, 361-364 (1996).
6. De Rosa V, Mangoni di Stefano ML, Brunetti A et al.: Computed tomography and second look surgery in ovarian cancer patients: correlation, actual role and limitations of CT scan. Eur. J. Gynaecol. Oncol. 16, 123-129 (1995).
7. Nakamoto Y, Saga T, Ishimori T et al.: Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. Am. J. Radiol. 176, 1449-1454 (2001).
8. Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC: Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol. Oncol. 85, 53-58 (2002).
9. Bristow RE, del Carmen MG, Pannu HK et al.: Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol. Oncol. 90, 519-528 (2003).
10. Onda T, Yoshikawa H, Yasugi T, Yamada M, Matsumoto K, Taketani Y: Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br. J. Cancer 92, 1026-1032 (2005)
11. Look M, Chang D, Sugarbaker PH: Longterm results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int. J. Gynecol. Cancer 13, 764-770 (2003).
12. Eisenkop SM, Friedman RL, Spirtos NM: The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88, 144-153 (2000).
13. Gronlund B, Lundvall L, Christensen IJ, Knudsen JB, Hogdall C: Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. Eur. J. Surg. Oncol. 31, 67-73 (2005).
14. Gungor M, Ortac F, Arvas M, Kosebay D, Sonmezer M, Kose K: The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol. Oncol. 97, 74-79 (2005).
15. Zang RY, Li ZT, Tang J et al.: Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 100, 1152-1161 (2004).
16. Scarabelli C, Gallo A, Carbone A: Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol. Oncol. 83, 504-512 (2201).
17. Munkarah AR, Coleman RL: Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol. Oncol. 95, 273-280 (2004).
18. Leitao MM, Kardos S, Barakat RR, Chi DS: Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol. Oncol. 95, 181-188 (2004).
19. Kavanagh J, Tresukosol D, Edwards C et al.: Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J. Clin. Oncol. 13, 1584-1588 (1995).
20. Bolis G, Scarfone G, Giardina G et al.: Carboplatin alone vs. carboplatin plus epidoxorubicin as second line therapy for cisplatin or carboplatin-sensitive ovarian cancer. Gynecol. Oncol. 81, 3-9 (2001).
21. Dizon DS, Hensley ML, Poynar EA et al.: Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J. Clin. Oncol. 20(5), 1238-1247 (2002).
22. Rose PG, Fusco N, Fluellen L, Rodriguez M: Second line therapy with paclitaxel and carboplatin for recurrent disease following first line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J. Clin. Oncol. 16(4), 1494-1497 (1998).
23. Eltabbakh GH, Yildirim Z, Adamowicz R: Paclitaxel and carboplatin as second-line therapy in women with platinum-sensitive ovarian carcinoma treated with platinum and paclitaxel as first-line therapy. Am. J. Clin. Oncol. 27(1), 46-50 (2004)
24. Watanabe Y, Nakai H, Ueda H, Hoshiai H: Evaluation of weekly low dose paclitaxel and carboplatin treatment for patients with platinum sensitive relapsed ovarian cancer. Gynecol. Oncol. 96, 323-329 (2005).
25. Kikuchi A, Sakamoto H, Yamamoto T: Weekly carboplatin and paclitaxel is safe, active, and well-tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy. Int. J. Gynecol. Cancer 15, 45-49 (2005).
26. Parmar MK, Ledermann JA, Colombo N et al.: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/ AGO-OVAR-2.2 trial. Lancet 361,2099-2106 (2003).
27. Trimble EL, Adams JD, Vena D et al.: Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J. Clin. Oncol. 11, 2405-2410 (1993).
28. Gore ME, Levy V, Rustin G et al.: Paclitaxel (taxol) in relapsed and refractory ovarian cancer: the UK and Eire Experience. Br. J. Cancer 72, 1016-1019 (1995).
29. Eisenhauer E, ten Bokkel Huinink WW, Swenerton KD et al.: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high dose versus low-dose and long versus short infusion. J. Clin. Oncol. 12, 2654-2666 (1994).
30. Cantu MG, Buda A, Parma G et al.: Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide. doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J. Clin. Oncol. 20, 1232-1237 (2002).
31. Andersson H, Horvath G, Mellqvist L, Westberg R: Taxol given weekly in advanced previously treated ovarian carrinomas - a pilot study. Int. J. Gynecol. Cancer 7, 262-266 (1997).
32. Rosenberg P, Andersson H, Boman K et al.: Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol. 41, 418-424 (2002).
33. Havrilesky LJ, Alvarez AA, Sayer RA et al.: Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol. Oncol. 88, 51-57 (2002).
34. Niwa Y, Nakanishi T, Kuzuya K, Nawa A, Mizutani S: Salvage treatment with docetaxel for recurrent epithelial ovarian cancer. Int. J. Clin. Oncol. 8, 343-347 (2003).
35. Rose PG, Blessing JA, Ball HG et al.: A Phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 88, 130-135 (2003).
36. Oishi T, Kigawa J, Fujiwara K et al.: A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer. Gynecol. Oncol. 90, 421-424 (2003).
37. Beldermann F, Lauschner I, Geberth M et al.: Chemotherapy with carboplatin/docetaxel for primary and recurrent epithelial ovarian cancer. Proc. Am. Soc. Clin. Oncol, 21, 176b (2002).
38. Bookman MA: Gemcitabine monotherapy in recurrent ovarian cancer: from bench to the clinic. Int. J. Gynecol. Cancer 15, S12-S17 (2005).
39. von Minckwitz G, Bauknecht T. Visseren-Grul CM, Neijt JP: Phase II study of gemcitabine in ovarian cancer. Ann. Oncol. 10, 853-855 (1999).
40. D'Agostino G, Amant F, Berteloot P, Scambia G, Vergote I: Phase II study of gemcitabine in recurrent platinum- and paclitaxel-resistant ovarian cancer. Gynecol. Oncol. 88, 266-269 (2003).
41. Rose PG: Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma. Int. J. Gynecol. Cancer 15, S18-S22 (2005).
42. Kose MF, Sufliarsky J, Beslija S et al.: A Phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma. Gynecol. Oncol. 96, 374-380 (2005).
43. Villella J, Marchetti D, Odunsi K, Rodabaugh K, Driscoll D, Lele S: Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma. Gynecol. Oncol. 95, 539-545 (2004).
44. Garcia AA, O'Meara A, Bahador A et al.: Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol. Oncol. 93, 493-498 (2004).
45. Sehouli J: Review of gemcitabine-based combinations for platinum-resistant ovarian cancer. Int. J. Gynecol. Cancer 15(1), 23-30 (2005).
46. Jungnelius JU, Ridderheim M, Perren T et al.: Optimal sequence leads to improved dose delivery for gemcitabine (G)/paclitaxel (P) combination in recurrent ovarian cancer: a Phase I study. Proc. Am. Soc. Clin. Oncol. 21, 223a (2002) (Abstract 890).
47. Greggi S, Salerno MG, D'Agostino G etal.: Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. Oncology 60, 19-23 (2001).
48. Rose PG: Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 10, 205-214 (2005).
49. Gordon AN, Tonda M, Sun S et al.: Longterm survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a Phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol. 95, 1-8 (2004).
50. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ: Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19, 3312-3322 (2001).
51. Uyar D, Kulp B, Peterson G, Zanotti K, Markman M, Belinson J: Cardiac safety profile of prolonged (> 6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies. Gynecol. Oncol. 94, 147-151 (2004).
52. D'Agostino G, Ferrandina G, Ludovisi M et al.: Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br. J. Cancer 89, 1180-1184 (2003).
53. Herzog T: Clinical experience with topotecan in relapsed ovarian cancer. Gynecol. Oncol. 90, S3-S7 (2003).
54. Homesley HD, Hall DJ, Marin DA et al.: A dose escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol. Oncol. 83, 394-399 (2001).
55. Morris RT: Weekly topotecan in the management of ovarian cancer. Gynecol. Oncol. 90, S34-S38 (2003).
56. Levy T, Inbar M, Mencer J. Grisaru D, Glexerman M, Safra T: Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol. Oncol. 95, 686-690 (2004)
57. ten Bokkel Huinink W, Gore M, Carmichael J et al.: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 15, 2183-2193 (1997).
58. Eckhardt S, Hernadi Z, Thurzo L et al.: Phase II clinical evaluation of etoposide (VP-16-213, VePesid) as second-line treatment in ovarian cancer. Results of the South-East European Oncology Group (SEEOG) study. Oncology 47, 289-295 (1990).
59. de Wit R, van der Burg ME, Gaast A, Logmans A, Stoter G, Verweij J: Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Ann. Oncol. 5, 656-657 (1994).
60. Rose PG, Blessing JA, Mayer AR, Homesley HD: Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 16, 405-410 (1998).
61. Bookman MA: Developmental chemotherapy in advance ovarian cancer: incorporation of newer cytotoxic agents in a Phase III randomized trial of the Gynecologic Oncology Group (GOG-0182). Semin. Oncol. 29, S20-S31 (2002).
62. Sood AK, Lush R, Geisler JP et al.: Sequential intra-peritoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma. Clin. Cancer Res. 10, 6080-6085 (2004).
63. Gronlund B, Engelholm SA, Horvath G, Maenpaa J, Ridderheim M: Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Cancer 103, 1388-1396 (2005).
64. Eltabbakh GH, Piver SM, Hempling RE, Recio FO, Blumenson LE: Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer. Gynecol. Oncol. 71, 190-195 1998).
65. Firat S, Erickson B: Selective irradiation for the treatment of recurrent ovarian carcinoma involving the vagina or rectum. Gynecol. Oncol. 80, 213-220 (2001).
66. Dowdy SC, Medtzinger DS, Gebhart JB et al.: Salvage whole-abdominal radiation therapy after second-look laparotomy or secondary debulking surgery in patients with ovarian cancer. Gynecol. Oncol. 96, 389-394 (2005).
67. Albuuerque KV, Singla R, Potkul RK et al.: Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer. Gynecol. Oncol. 96, 701-704 (2005).
68. Zanon C, Clara R, Chiappino I et al.: Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J. Surg. 28, 1040-1045 (2004).
69. Hasenburg A, Tong XW, Fischer DC et al.: Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol. Oncol. 83, 549-554 (2001).
70. Madhusudan S, Tamir A, Bates N et al.: A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer over expressing HER-2/neu oncogene. Clin. Cancer Res. 10, 2986-2996 (2004).